Section for Psychiatry, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden.
Clinical addiction research unit, Malmö Addiction Center, Region Skåne, Malmö, Sweden.
JMIR Res Protoc. 2024 Aug 16;13:e56315. doi: 10.2196/56315.
Gaming disorder (GD) is a new official diagnosis in the International Classification of Diseases, 11th Revision, and with its recognition, the need to offer treatment for the condition has become apparent. More knowledge is needed about the type of treatment needed for this group of patients.
This study aims to evaluate the effectiveness and acceptability of a novel module-based psychological treatment for GD based on cognitive behavioral therapy and family therapy.
This study is a nonrandomized intervention study, with a pretest, posttest, and 3-month follow-up design. It will assess changes in GD symptoms, psychological distress, and gaming time, alongside treatment satisfaction, working alliance, and a qualitative exploration of patients' and relatives' experiences of the treatment.
This study started in March 2022 and the recruitment is expected to close in August 2024.
This study evaluates the effectiveness and acceptability of a psychological treatment for patients with problematic gaming behavior and GD. It is an effectiveness trial and will be conducted in routine care. This study will have high external validity and ensure that the results are relevant for a diverse clinical population with psychiatric comorbidity.
ClinicalTrials.gov NCT06018922; https://clinicaltrials.gov/study/NCT06018922.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/56315.
游戏障碍(GD)是《国际疾病分类》第 11 次修订版中的一个新的官方诊断,随着其得到认可,为这种疾病提供治疗的需求变得明显。我们需要更多地了解这组患者所需的治疗类型。
本研究旨在评估一种基于认知行为疗法和家庭疗法的新型基于模块的心理治疗对 GD 的有效性和可接受性。
这是一项非随机干预研究,采用前测、后测和 3 个月随访设计。它将评估 GD 症状、心理困扰和游戏时间的变化,以及治疗满意度、工作联盟,以及对患者和亲属对治疗体验的定性探索。
该研究于 2022 年 3 月开始,预计招募将于 2024 年 8 月结束。
本研究评估了针对有问题游戏行为和 GD 患者的心理治疗的有效性和可接受性。这是一项有效性试验,将在常规护理中进行。该研究将具有很高的外部有效性,并确保结果与具有精神共病的不同临床人群相关。
ClinicalTrials.gov NCT06018922;https://clinicaltrials.gov/study/NCT06018922。
国际注册报告标识符(IRRID):DERR1-10.2196/56315。